Gossamer Bio, Inc.
GOSS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.02 | 0.05 | 0.37 |
| FCF Yield | -1.69% | -77.32% | -102.17% | -22.51% |
| EV / EBITDA | -9.04 | -2.24 | -1.41 | -4.05 |
| Quality | ||||
| ROIC | -22.45% | -66.76% | -96.26% | -75.01% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.06 | 0.89 | 0.82 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 97.82% | 15.12% | 1.58% | 5.33% |
| Safety | ||||
| Net Debt / EBITDA | -3.92 | -1.05 | -0.54 | -0.01 |
| Interest Coverage | -5.20 | -13.60 | -15.75 | -11.12 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -37.99 |
| Cash Conversion Cycle | 16.99 | -459.97 | -120.24 | -238.77 |